{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Taxane+Chemotherapy&page=26", "query": { "intervention": "Taxane Chemotherapy", "page": 26 }, "page_size": 10 }, "pagination": { "page": 26, "page_size": 10, "total_count": 1450, "total_pages": 145, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Taxane+Chemotherapy&page=27&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Taxane+Chemotherapy&page=25&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-16T09:30:49.898Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06623422", "title": "A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Intismeran autogene", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 680, "start_date": "2024-10-21", "completion_date": "2038-01-26", "has_results": false, "last_update_posted_date": "2026-10-02", "last_synced_at": "2026-10-16T09:30:49.898Z", "location_count": 52, "location_summary": "Gilbert, Arizona • Tucson, Arizona • Fullerton, California + 40 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Fullerton", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06623422" }, { "nct_id": "NCT06042569", "title": "Dose-Reduced Docetaxel With Cyclophosphamide for the Treatment of Vulnerable Older Women With Stage I-III HER2 Negative Breast Cancer, the DOROTHY Trial", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Anatomic Stage I Breast Cancer AJCC v8", "Anatomic Stage II Breast Cancer AJCC v8", "Anatomic Stage III Breast Cancer AJCC v8", "HER2-Negative Breast Carcinoma" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Medical Chart Review", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "65 Years", "maximum_age": null, "sex": "ALL", "summary": "65 Years and older" }, "enrollment_count": 174, "start_date": "2024-09-16", "completion_date": "2030-03-20", "has_results": false, "last_update_posted_date": "2026-04-17", "last_synced_at": "2026-10-16T09:30:49.898Z", "location_count": 3, "location_summary": "Duarte, California • Boston, Massachusetts • Rochester, New York", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Rochester", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06042569" }, { "nct_id": "NCT00021060", "title": "Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Advanced, Metastatic, or Recurrent Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Adenocarcinoma of the Lung", "Bronchoalveolar Cell Lung Cancer", "Large Cell Lung Cancer", "Recurrent Non-small Cell Lung Cancer", "Stage IIIB Non-small Cell Lung Cancer", "Stage IV Non-small Cell Lung Cancer" ], "interventions": [ { "name": "paclitaxel", "type": "DRUG" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "bevacizumab", "type": "BIOLOGICAL" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 842, "start_date": "2002-08", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-02-27", "last_synced_at": "2026-10-16T09:30:49.898Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00021060" }, { "nct_id": "NCT00004888", "title": "Combination Chemotherapy With or Without Trastuzumab in Treating Women With Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Breast Cancer", "Stage IV Breast Cancer" ], "interventions": [ { "name": "pegylated liposomal doxorubicin hydrochloride", "type": "DRUG" }, { "name": "docetaxel", "type": "DRUG" }, { "name": "trastuzumab", "type": "BIOLOGICAL" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 84, "start_date": "2001-01", "completion_date": "2009-05", "has_results": true, "last_update_posted_date": "2014-05-23", "last_synced_at": "2026-10-16T09:30:49.898Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004888" }, { "nct_id": "NCT00755313", "title": "Effects of Chemotherapy on the Brain in Women With Newly Diagnosed Early-Stage Breast Cancer", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Breast Cancer", "Chemotherapeutic Agent Toxicity", "Cognitive/Functional Effects", "Fatigue", "Long-term Effects Secondary to Cancer Therapy in Adults", "Neurotoxicity", "Psychosocial Effects of Cancer and Its Treatment" ], "interventions": [ { "name": "trastuzumab", "type": "BIOLOGICAL" }, { "name": "aromatase inhibition therapy", "type": "DRUG" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "docetaxel", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "metabolic assessment", "type": "OTHER" }, { "name": "questionnaire administration", "type": "OTHER" }, { "name": "study of socioeconomic and demographic variables", "type": "OTHER" }, { "name": "cognitive assessment", "type": "PROCEDURE" }, { "name": "positron emission tomography", "type": "PROCEDURE" }, { "name": "fludeoxyglucose F 18", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER", "PROCEDURE", "RADIATION" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "35 Years", "maximum_age": "80 Years", "sex": "FEMALE", "summary": "35 Years to 80 Years · Female only" }, "enrollment_count": 81, "start_date": "2007-05", "completion_date": "2014-06-06", "has_results": false, "last_update_posted_date": "2017-11-24", "last_synced_at": "2026-10-16T09:30:49.898Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00755313" }, { "nct_id": "NCT03574779", "title": "A Study to Evaluate the Efficacy and Safety of Novel Treatment Combinations in Participants With Ovarian Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ovarian Neoplasms" ], "interventions": [ { "name": "Niraparib", "type": "DRUG" }, { "name": "TSR-042", "type": "BIOLOGICAL" }, { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Tesaro, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 77, "start_date": "2018-11-15", "completion_date": "2025-03-31", "has_results": true, "last_update_posted_date": "2025-07-15", "last_synced_at": "2026-10-16T09:30:49.898Z", "location_count": 19, "location_summary": "Birmingham, Alabama • Los Angeles, California • San Francisco, California + 15 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Ventura", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03574779" }, { "nct_id": "NCT00273546", "title": "Induction Chemotherapy Comparing Taxotere® Cisplatin and 5-Fluorouracil (TPF) With Standard Cisplatin and 5-Fluorouracil (PF) Followed by Chemoradiation in Locally Advanced Head and Neck Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "XRP6976 (Docetaxel/Taxotere)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 500, "start_date": "1999-05", "completion_date": "2006-02", "has_results": false, "last_update_posted_date": "2009-04-29", "last_synced_at": "2026-10-16T09:30:49.898Z", "location_count": 1, "location_summary": "Bridgewater, New Jersey", "locations": [ { "city": "Bridgewater", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00273546" }, { "nct_id": "NCT00242203", "title": "Evaluation of Chemotherapy Prior to Surgery With or Without Zometa for Women With Locally Advanced Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Neoplasms" ], "interventions": [ { "name": "Zometa", "type": "DRUG" }, { "name": "Epirubicin", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "External beam radiation", "type": "RADIATION" }, { "name": "Modified radical mastectomy or breast conserving surgery with axillary lymph node dissection", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "RADIATION", "PROCEDURE" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 120, "start_date": "2002-10", "completion_date": "2011-05", "has_results": false, "last_update_posted_date": "2013-08-13", "last_synced_at": "2026-10-16T09:30:49.898Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT00242203" }, { "nct_id": "NCT00324805", "title": "Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Stage IB Lung Non-Small Cell Carcinoma AJCC v7", "Stage IIA Lung Non-Small Cell Carcinoma AJCC v7", "Stage IIB Lung Non-Small Cell Carcinoma AJCC v7", "Stage IIIA Lung Non-Small Cell Cancer AJCC v7" ], "interventions": [ { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Gemcitabine Hydrochloride", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pemetrexed Disodium", "type": "DRUG" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Vinorelbine Tartrate", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1501, "start_date": "2007-07-19", "completion_date": "2025-01-31", "has_results": true, "last_update_posted_date": "2026-06-23", "last_synced_at": "2026-10-16T09:30:49.898Z", "location_count": 1139, "location_summary": "Anniston, Alabama • Huntsville, Alabama • Mobile, Alabama + 712 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT00324805" }, { "nct_id": "NCT00206453", "title": "Extension Neoadjuvant Taxotere: Study of the Effects of Taxotere in Patients With Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Taxotere", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Baylor Breast Care Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 25, "start_date": "2002-01", "completion_date": "2005-01", "has_results": false, "last_update_posted_date": "2013-02-05", "last_synced_at": "2026-10-16T09:30:49.898Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00206453" } ] }